Neptune Technologies preclinical data

In rats with severe dyslipidemic and metabolic syndrome, human equivalent dosing with once-daily 0.5 or 2.5 g of Acasti Pharma Inc.'s CaPre long-chain omega-3 phospholipids reduced C-reactive protein...